Thymic peptide
Thymalin
Thymalin is described as an immunomodulatory drug containing a polypeptide extract of thymus; the app lists a half-life of about 0.4 hours, and no half-life figure was located in the records retrieved.1
Thymalin after one dose: 50% at ~0.4 h, 25% at 0.8 h, 12.5% at 1.2 h.
Drawn from the half-life in the app's model, ~0.4 h. The model's figures
- Compound
- Thymalin
- Symbol
- THY
- Family
- Healing peptides
- Parts
- 11
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
The 2023 paper by Linkova and colleagues describes thymalin as "an immunomodulatory drug containing a polypeptide extract of thymus", and names KE and EW dipeptides as its active substances.1 Morozov and Khavinson, writing in the International Journal of Immunopharmacology in 1997, report that natural thymic peptides were isolated from calf thymus by mild acid extraction and that the pharmaceutical containing them is thymalin.2 The app's notes describe thymalin as a dipeptide (Lys-Glu) derived from thymic extract. The sources above describe a polypeptide extract or complex that contains dipeptides, so the app's one-dipeptide description is narrower than the sources.1,2 The app files thymalin under thymic peptides and grades its evidence as emerging.
Of 293 PubMed records matching "thymalin", the first 20 were screened and ClinicalTrials.gov returned 0 studies; the 2003 study and the 2020 and 2023 laboratory papers share an author, Khavinson, at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson and Morozov (Neuro Endocrinology Letters, 2003) followed 266 elderly and older persons for 6 to 8 years and report lower mortality in groups given thymalin.3 Kuznik and colleagues (Advances in Gerontology, 2022) compared hospital mortality in severe COVID-19 across three treatment groups.4 No ClinicalTrials.gov entry for thymalin and no DailyMed label were identified.
How it works
Sources in this part
The mechanism is studied mainly in cells and by computer modelling, not in people. Morozov and Khavinson report that "Both natural and synthetic pharmaceuticals activated T-cell differentiation"; the natural pharmaceutical is thymalin, the synthetic ones are dipeptide-based (Thymogen and a dipeptide termed Vilon), and the record does not state the model used.2 Khavinson and colleagues (Bulletin of Experimental Biology and Medicine, 2020) report in their summary that thymalin "reduced the expression of CD44 (stem cell marker) and CD117 (molecule of the intermediate stage of HSC differentiation) by 2-3 times and increased the expression of CD28 (marker of mature T lymphocytes) by 6.8 times" in human hematopoietic stem cells.5 The authors call this an indirect indication, writing that it "indirectly indicates that thymalin stimulated differentiation of CD117+ cells into mature CD28+T lymphocytes".5 The retrieved text of that paper gives no funding statement or conflict-of-interest statement, and all seven authors list the St. Petersburg Institute of Bioregulation and Gerontology.5 Zhukova and colleagues (Bulletin of Experimental Biology and Medicine, 2018) report an "antitumor effect of Thymalin in doses lower than the therapeutic doses" in outbred male rats with transplanted sarcoma 45, an animal result that is not a finding in people.6
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.4 h
- Bioavailability
- 80%
- Typical dose
- 5–10 mg/day
- Route
- IM / SubQ
- Time to peak
- ~0.5 h
Sources in this part
The second column holds the app's figures; the third holds what the records retrieved report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.4 h (about 24 minutes) | No half-life figure was located in the records retrieved |
| Bioavailability | 80% | No bioavailability figure was located in the records retrieved |
| Time to peak | ~0.5 h | No time-to-peak figure was located in the records retrieved |
| Duration of activity | ~3 h | No figure was located in the records retrieved |
| Routes | IM, SubQ | None of the records retrieved states the route used in its study |
The app's one-compartment model and its half-life of about 0.4 hours rest on the app's own notes, which give a range of 15 to 30 minutes; none of the sources retrieved confirms or contradicts them. Thymalin is described as a polypeptide extract whose active substances include the KE and EW dipeptides, and the sources retrieved give no half-life for the extract or for the dipeptides.1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Khavinson and Morozov, Neuro Endocrinology Letters 20033 | PubMed lists it as a randomized controlled trial; the record gives no allocation method and no group sizes3 | 266 elderly and older persons3 | Observed for 6 to 8 years; bioregulators applied for the first 2 to 3 years; dose not given in the record3 | Mortality lower by 2.0-2.1-fold in the thymalin group, 1.6-1.8-fold with epithalamin, 2.5-fold with both, and 4.1 times with both given annually for 6 years, each against control3 |
| Khavinson and Morozov, Advances in Gerontology 20027 | Review article by the same authors reporting the same 266-person assessment7 | 266 elderly and older persons7 | 6 to 8 years of observation; bioregulators applied for the first 2 to 3 years7 | Mortality 2.0-2.1-fold lower among thymalin-treated patients and 4.1-fold lower in the group given thymalin with epithalamin annually for 6 years, against control7 |
| Kuznik and colleagues, Advances in Gerontology 20224 | Three-group comparison in severe COVID-19; the record does not state whether allocation was randomized4 | Middle-aged and elderly patients with severe COVID-19; group sizes not given in the record4 | Basic therapy plus thymalin against basic therapy alone and basic therapy plus tocilizumab; dose and length not given in the record4 | Hospital mortality 40,9% (standard therapy), 28,4% (tocilizumab) and 20,6% (thymalin)4 |
| Musienko, Likars'ka Sprava 19998 | Patients examined before and after a course of treatment; no control group is described in the record8 | 15 patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism, aged 45 to 72 years8 | Dose and length not given in the record8 | A significant decrement in the power of alpha rhythm in the anterocentral regions of the brain on EEG mapping, which the author reads as an improvement in cortical neurodynamics8 |
For all four rows only the PubMed record was read, not the full paper, so group sizes, dosing and adverse events may sit in the full texts.
Deeper analysis: Khavinson and Morozov, Neuro Endocrinology Letters 2003
The authors are from the St. Petersburg Institute of Bioregulation and Gerontology, and the record names a second centre, the Institute of Gerontology of the Ukrainian Academy of Medical Sciences in Kiev.3 The study assessed "the geroprotective effects of thymic (Thymalin) and pineal (Epithalamin) peptide bioregulators" in 266 people over 6 to 8 years.3 Besides mortality, the authors report a "2.0-2.4-fold decrease in acute respiratory disease incidence" and reduced incidence of the clinical manifestations of ischemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis, against control.3 The mortality figures are fold decreases against a control group; the record gives no deaths per group, no confidence intervals and no p-values.3 The record reports no adverse events or discontinuations, so the safety of the thymalin groups cannot be read from it.3 The record states no limitations and no funder, and does not list a conflict-of-interest statement; the conclusion is stated as confirming "the high geroprotective efficacy of Thymalin and Epithalamin".3 The thymalin plus epithalamin group given treatment annually for 6 years is described as "a separate group of patients" in the record, which does not say how that group was formed.3
Deeper analysis: Linkova and colleagues, International Journal of Molecular Sciences 2023
The study combined molecular docking of the EW and KE dipeptides to DNA, database analysis of target genes, and an in vitro model of inflammation in human blood cells; it is not a study in people.1 Blood "samples were obtained from four donors", and the peptides were incubated at "a concentration of 1 mg/mL" with lipopolysaccharide-stimulated mononuclear cells.1 In stimulated cells, TNF-α release fell "by 2.2 times for Thymalin", and thymalin reduced IL-1β synthesis "by 2.7 times".1 The same paper reports effects in the other direction: in unstimulated cells thymalin "stimulated the release of IL-6 by non-LPS-treated PBMCs by about four times", and "did not have a significant effect on TNF-α synthesis by control cells".1 The authors describe the experiments in unstimulated cells as pilot experiments, and these were mainly repeated 2 times.1 The authors state that the work "received no external funding" and declare no conflict of interest; Khavinson is among the authors and the paper's affiliations include the St. Petersburg Institute of Bioregulation and Gerontology.1 No limitations passage was identified in the full text, and the in vitro results come from four blood donors in a model of inflammation, so they do not show an effect in patients.1
Deeper analysis: Kuznik and colleagues, Advances in Gerontology 2022
The authors are at Chita State Medical Academy and affiliated hospitals and universities in Russia, and the record states no funder or conflict-of-interest statement.4 The last author, Linkova N S, is also an author of the 2020 and 2023 papers cited here, which list Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology.4,5,1 The authors report that thymalin "increased the number of lymphocytes and monocytes by 2 times" and "decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively".4 They conclude that thymalin "meets the principles of pathogenic therapy for severe COVID-19 of middle aged and elderly patients to a greater extent" than tocilizumab.4 The record gives no group sizes, dose, test statistics or adverse events, so the mortality percentages cannot be judged for chance or for baseline differences between groups.4
Side effects reported
None of the five PubMed records read for adverse events (14523363, 12577695, 36169363, 10424021 and 29797130) reports any for thymalin; only the PubMed records, not the full papers, were read, so safety cannot be read from them. The app lists no health markers to monitor for thymalin.
Regulatory and anti-doping status
Sources in this part
The 2026 WADA Prohibited List text retrieved does not name thymalin.9 Its S0 class covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List" and that has "no current approval by any governmental regulatory health authority for human therapeutic use".9 Whether S0 applies to thymalin depends on its approval status, which the records retrieved do not state.9 No thymalin label was identified in DailyMed.
What is not known
- No half-life, bioavailability, time-to-peak or duration figure for thymalin was located, so the app's figures have no figure from a source to sit beside them.
- No dose or schedule was given in any of the records read, so the app's range of 5 to 10 mg/day has no dose from a source to sit beside it.
- Only the PubMed records of the controlled human studies listed above were read, and only the first 20 of 293 PubMed records for "thymalin" were screened, so full-text reports of controlled studies were not assessed.
- The mortality figures of 2003 come from one research group, and independent replication was not identified in the records screened.
Frequently asked questions
What is thymalin?
What is the half-life of thymalin?
The app lists about 0.4 hours (about 24 minutes), and no half-life figure from a source was located to set beside it.
Is thymalin banned by WADA?
Has thymalin been tested in a randomized trial?
PubMed lists the 2003 Khavinson and Morozov study of 266 older people as a randomized controlled trial, and the record does not describe how people were allocated.3
What did the 2003 study report about mortality?
Does thymalin lower cytokines in cells?
What side effects have been reported for thymalin?
None of the five PubMed records read for adverse events reports any for thymalin; only the PubMed records, not the full papers, were read, so safety cannot be read from them.
Guides, tools and comparisons
References
- Linkova N, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci 2023. PMC10488166
- Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol 1997. PMID 9637345
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. PMID 14523363
- Kuznik BI, et al. Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin. Adv Gerontol 2022. PMID 36169363
- Khavinson VK, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med 2020. PMC7686446
- Zhukova GV, et al. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med 2018. PMID 29797130
- Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin. Adv Gerontol 2002. PMID 12577695
- Musienko GV. Thymalin in the combined treatment of parkinsonism patients. Lik Sprava 1999. PMID 10424021
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list